Journal of Clinical Trials
Open Access

Abstract

Impact of Levocetirizine on Quality of Life and Daily Activities in Patients with Chronic Urticaria

Kiran Godse, Meghna Singh, Roheet Rathod, Akhila Paspulate, Krishna Chaitanya Veligandla, Rahul Rathod, Devesh Kumar Joshi* and Bhavesh P Kotak

Background: Urticaria negatively impacted patients’ quality of life, day to day activities and productivity at work place. The present study evaluated effectiveness of Levocetirizine on symptom control, quality of life and work productivity in patients with urticaria.

Methodology: The study was a prospective, open-labelled, single-arm, observational study among patients with chronic urticaria. It was initiated after necessary approval from the Institutional Ethics committee. Levocetirizine was prescribed as 5 mg or 10 mg once a day evening oral dose for consecutive 7 days at bed time. Urticaria symptom control such as size, frequency of wheal, duration of pruritis, quality of Life using SF-12 scale, degree of sleepiness applying Stanford Sleepiness Scale and work output and activity impairment using WPAI questionnaires were assessed.

Results: Following administration of oral Levocetirizine, effective symptom control, as indicated by significant reductions in the mean symptom scores like size, frequency of wheal and duration of pruritis were observed. While quality of life significantly improved, there was no change in degree of sleepiness at morning and afternoon hours. However, Levocetirizine produced modest degree of somnolence at night-time though it did not affect quality of life as compared to baseline.

Conclusion: Levocetirizine alleviated clinical symptoms while having no significant adverse effects on daytime somnolence and quality of life among patients with urticaria.

Published Date: 2023-05-11; Received Date: 2023-04-11